Abstract： Objective： To observe the clinical effect of Dengzhan Shengmai Capsules combined with routine western medicine for stable angina pectoris of coronary heart disease (CHD). Methods：A total of 104 cases of CHD patients with stable angina pectoris of qi and yin co-deficiency type were divided into the treatment group and the control group according to the random number table method ， with 54 and 50 cases in each group respectively. Both groups were treated with routine symptomatic treatment of western medicine，and the treatment group was additionally treated with Dengzhan Shengmai Capsules； both groups were treated for 3 months. Before and after treatment，the traditional Chinese medicine (TCM) syndrome scores were evaluated， and the heart function indexes including cardiac output (CO)， left ventricular ejection fraction (LVEF) and left ventricular end systolic diameter (LVESD)，inflammatory indexes including serum high- sensitivity C- reactive protein (hs- CRP) and interleukin- 6 (IL- 6)， systolic blood pressure (SBP)， heart rate (HR)， fasting blood glucose (FBG)， blood lipid indexes including low- density lipoprotein cholesterol (LDL-C)，high-density lipoprotein cholesterol (HDL-C)，triglycerides (TG) and total cholesterol (TC)，and liver and kidney function indexes including alanine aminotransferase (ALT)，aspartate transaminase (AST)，urea，and creatinine (Cr) were measured. Clinical effects were evaluated in the two groups. The incidence of cardiovascular adverse events and adverse reactions were calculated. Results： After treatment，the total effective rate of clinical effect was 94.44% in the treatment group，higher than that of 82.00% in the control group，the difference being significant (P＜0.05). TCM syndrome scores in the two groups were decreased when compared with those before treatment (P＜0.05)，and TCM syndrome scores in the treatment group were lower than those in the control group (P＜0.05). The values of CO and LVEF in the two groups were higher than those before treatment，and LVESD values were lower than those before treatment， differences being significant (P＜0.05)； the values of CO and LVEF in the treatment group were higher than those in the control group，and LVESD value in the treatment group was lower than that in the control group， differences being significant (P＜0.05). The levels of HR and SBP in the two groups were lower than those before treatment (P＜0.05)，and FBG level in the treatment group was lower than that before treatment and that in the control group after treatment (P＜0.05). The levels of hs- CRP， IL-6，TG，TC，and LDL-C in the two groups were lower than those before treatment (P＜0.05)，and the above indexes in the treatment group were lower than those in the control group in average (P＜0.05). The levels of HDL- C in the two groups were higher than those before treatment (P＜0.05)， and the level of HDL- C in the treatment group was high than that in the control group (P＜0.05). There was no significant difference being found in the comparison of levels of AST，ALT，Cr，and UREA in the two groups before and after treatment (P＞0.05). During treatment， there was no significant difference being found in the comparison of the incidence of cardiovascular adverse events and adverse drug reactions between the two groups (P＞0.05). Conclusion： For CHD patients with stable angina pectoris， Dengzhan Shengmai Capsules combined with routine symptomatic treatment of western medicine is better than the simple use of routine western medicine treatment in the effective improvement of clinical effects， the remission of clinical symptoms，the improvement of the heart function，the reduction of inflammatory responses of the body，and the regulation of levels of heart rate，blood pressure，blood glucose，and blood lipid，so as to effectively control the disease，with no significant impact on liver and kidney function，few cardiovascular adverse events and adverse reactions，and high medication safety.